Loss of glutamatergic synapses is thought to be a key cellular pathology associated with neuropsychiatric disorders including schizophrenia (SCZ) and major depressive disorder (MDD). Genetic and cellular studies of SCZ and MDD using in vivo and in vitro systems have supported a key role for dysfunction of excitatory synapses in the pathophysiology of these disorders. Recent clinical studies have demonstrated that the estrogen, 17β-estradiol can ameliorate many of the symptoms experienced by patients. Yet, to date, our understanding of how 17β-estradiol exerted these beneficial effects is limited. In this study, we have tested the hypothesis that 17β-estradiol can restore dendritic spine number in a cellular model that recapitulates the loss of synapses associated with SCZ and MDD. Ectopic expression of wildtype, mutant or shRNA-mediated knockdown of Disrupted in Schizophrenia (DISC1) reduced dendritic spine density in primary cortical neurons. Acute or chronic treatment with 17β-estradiol increased spine density to control levels in neurons with altered DISC1 levels. In addition, 17β-estradiol reduced the extent to which ectopic wildtype and mutant DISC1 aggregated. Furthermore, 17β-estradiol also caused the enrichment of synaptic proteins at synapses and increased the number of dendritic spines containing PSD-95 or that overlapped with the pre-synaptic marker bassoon.
Introduction
Glutamatergic synapse dysfunction is thought to be a key cellular hallmark of a number of neuropsychiatric disorders including schizophrenia (SCZ) and major depressive disorder (MDD) [1] [2] [3] [4] . In the mammalian forebrain, the majority of excitatory glutamatergic synapses occur on specialized structures known as dendritic spines, which protrude off and decorate the dendrite of pyramidal neurons 4, 5 . Dendritic spines house the post-synaptic density (PSD), where a number of key synaptic proteins involved in synaptic transmission and signaling are located 4, 5 . Post-mortem studies have also shown that there are reduced dendritic spine numbers in the brains of patients with SCZ and MDD 2, [6] [7] [8] . Consistent with this genetic studies have linked a number of genes encoding for synaptic proteins or for proteins that regulate synapse structure or function with neuropsychiatric disorders including SCZ and MDD 1, 2, 4, [9] [10] [11] . Therefore, it has been suggested that regulating synapse protein and dendritic spine number may be a viable therapeutic strategy in the treatment of SCZ and/or MDD 6, 11, 12 .
The disrupted-in-schizophrenia 1 (DISC1) gene has been implicated in the pathophysiology of SCZ and MDD [13] [14] [15] [16] [17] . The association of DISC1 with neuropsychiatric disorders was originally identified through analysis of a large Scottish family where a balanced chromosomal translocation, associated with psychiatric illness 14 . This translocation is thought to lead either to a loss of DISC1 or the formation of a dominant-negative C-terminally truncated DISC1 protein 13, 16 .
DISC1 is a scaffold protein that is enriched at synapses where it interacts with a number of different proteins 13, 18 . DISC1 has been described to regulate dendrite spine morphology, number and glutamatergic transmission 13, 15 . While the contribution of DISC1 to the etiology of SCZ and MDD remains unclear and somewhat controversial 19, 20 , results from animal and cellular models have demonstrated that altering the expression levels of DISC1 protein results in a loss of dendritic spine density [21] [22] [23] [24] , a result consistent with that seen in postmortem studies of patients with SCZ or MDD 2, 4, 11 . Truncation of the C-terminal has been used extensively to model DISC1 pathology in cellular and transgenic models. Animal models expressing C-terminal truncated DISC1 constructs have been reported to display reduced spine density in vivo as well as in vitro 22, 23, 25, 26 .
The neurosteroid, 17β-estradiol, has been shown to be a potent neuromodulator, having positive effects on cognitive processes including learning and memory as well as mood 27, 28 . The effect of 17β-estradiol, the principal biologically active estrogen, on cognition is thought to be driven, in part, by activation of specific signaling pathways resulting in alternations in dendritic spine number and the trafficking of key synaptic proteins (reviewed in 13). Recently, clinical studies have shown that treatment with 17β-estradiol has beneficial effects for patients diagnosed with SCZ or MDD, when given as an adjunct treatment to ongoing antipsychotic or antidepressant therapies [29] [30] [31] [32] [33] [34] . However, the molecular and cellular mechanisms by which 17β-estradiol exert these beneficial effects are currently unknown. One possibility is that 17β-estradiol exerts its beneficial effects via the modulation of glutamatergic synapses 27, 35, 36 . However, this has not been tested directly in a cellular model of disease.
In this study, we have tested the hypothesis that 17β-estradiol can restore the number of excitatory synapses in a cellular model that recapitulates the loss of synapses associated with SCZ and MDD. To this end, we have utilized a cellular model of neuropsychiatric disorders, in the form of manipulating the expression levels of DISC1 to reduce dendritic spine density in primary neuronal cultures 21, 23, 37 .
Specifically, we have exogenously expressed wildtype rodent DISC1 or a C-terminal truncation mutant of rodent DISC1, which lacks amino acids 598-854, thus mimicking the truncated mutation proposed to be generated by the balance translocation associated with SCZ and MDD, or have used an shRNA approach to knockdown DISC1 expression 13, 21, 38 . Subsequently, we treated cells with 17β-estradiol for 30 minutes (acute) or for 4 days (chronic) to explore whether this neurosteroid could modulate dendritic spine density and synaptic protein expression at synapses in a cellular model, recapitulating aspects of the pathophysiology associated with SCZ and MDD. A number of studies have suggested that the aggregation of DISC1 might be important for psychiatric disease. An original study identified high molecular weight insoluble aggregates of DISC1 in patients specifically diagnosed with major mental illness including SZZ and MDD 39, 40 . Thus, we also investigated whether 17β-estradiol altered mutant or wildtype DISC1 aggregates, and further examined the sub-cellular distribution of endogenous DISC1 and its synaptic interacting proteins following treatment. Our results demonstrate that treatment with 17β-estradiol is sufficient to restore dendritic spine deficits to basal levels, whilst concurrently reducing DISC1 aggregates. Moreover, we go on to show that 17β-estradiol can modulate DISC1 enrichment at synapses, as well as its interacting partner, kalirin-7, a Rac-GEF known to regulate spine density 21 . Critically, we find that chronic treatment with 17β-estradiol increases spine density as well as the number of spines containing PSD-95 and that show overlap with bassoon. Thus, these data suggest that the mechanism by which 17β-estradiol is beneficial in the treatment of SCZ and MDD, may in part be driven by its ability to regulate excitatory glutamatergic synapses. DISC1 440 rabbit polyclonal (used at 1:250) has been previously described 41, 42 . The antigenic peptide was RTPHPEEEKSPLQVLQEWD, which is identical in human, mouse and rat. DISC1-440 consistently recognizes four major isoforms from rat brain lysates, including two bands at 130 kD and two around 100 kD 41, 42 . 17β-estradiol (E8875) was from Sigma. HA-DISC1WT (wildtype), HA-DISC1ΔCT
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Methods
Reagents
(mutant) and shRNA against rodent DISC1 constructs were kind gifts from A. Sawa (Johns Hopkins University); generation and validation of these constructs have previously been described 21, 38 . Both wildtype and mutant DISC1 constructs were generated based on rodent sequences; DISC1ΔCT lacks the C-terminal amino acids 598-854, and mimics the breakpoint associated with the balance translocation of DISC1 38, 43 .
Neuronal culture and transfections
Cortical neuronal cultures, consisting of mixed sexes, were prepared from E18 Sprague-Dawley rat embryos as described previously 44 . Chronic pharmacological treatments were performed by adding 17β-estradiol directly into media. Treatment started on the day of transfection and continued ever day until day 4. Cells were fixed 24 hours after the final treatment on day 5. Samples were then processed for ICC.
Immunocytochemistry (ICC)
Neurons were washed in PBS and then fixed in either 4% formaldehyde/4%
sucrose PBS for 10 minutes at room temperature followed by incubation in methanol pre-chilled to -20°C for 10 minutes at 4°C, or only in methanol (-20°C) for 20 minutes at 4°C. Fixed neurons were then permeabilized and blocked simultaneously (2% Normal Goat Serum, 5425S, New England Biolabs and 0.1% Triton X-100) before incubation in primary antibodies overnight and subsequent incubation with secondary antibodies the following day 44 . In the green/magenta colour scheme, colocalization is indicated by white overlap.
Quantitative Analysis of Spine Morphologies and Immunofluorescence
Confocal images of double-stained neurons were acquired with a Leica SP-5 confocal microscope using a 63x oil-immersion objective (Leica, N.A. 1.4) as a zseries, or with a Zeiss Axio Imager Z1, equipped with an ApoTome using a 63x oilimmersion objective (Carl Zeiss, N.A. 1.4). Two-dimensional maximum projection reconstructions of images were generated and linear density calculated using ImageJ/Fiji (https://imagej.nih.gov/ij/) 44 . Morphometric analysis was performed on spines from two dendrites (secondary or tertiary branches), totaling 100 µm, from 9 each neuron. Linear density and total gray value of each synaptic protein cluster was measured automatically using MetaMorph Software (Molecular Devices) 44 . Cultures directly compared were stained simultaneously and imaged with the same acquisition parameters. For each condition, 10-16 neurons from at least 3 separate experiments were used. Experiments were carried out blind to condition and on sister cultures.
Biochemistry cell fractionation
Crude synaptosome fractions were prepared from DIV 25 neurons following treatment with 17β-estradiol or vehicle for 30 minutes. Cells were lysed in homogenization buffer (320 mM sucrose; 5 mM Na4P2O7; 1 mM EDTA pH 8; and 10 mM HEPES pH 7.4 + protease inhibitors) and subsequently passed through a 21 gauge needle 15 times. Cell lysate was then centrifuged to remove the nuclear fraction and large cell organelles (P1 fraction) and yield the extranuclear fraction (S1). A portion of the S1 fraction was kept and the remaining was subjected to further fractionation by an additional spin. This yielded the cytosolic (S2) and crude synaptosome (P2) fractions; the P2 fraction was resuspended in homogenization buffer. Sample buffer was added to all samples, which were then denatured for 5 minutes at 95°C and stored at -80°C until used further. All samples were subsequently separated by SDS-PAGE and analyzed by Western Blotting with kalirin, DISC1, PSD-95 and β -actin antibodies. Quantification of bands was performed by measuring the integrated intensity of each band and normalizing to β -actin, for protein loading, using Image J.
Statistical Analysis
All statistical analysis were performed using Prism (GraphPad Software).
Differences in quantitative immunofluorescence, dendritic spine number were identified by Student's unpaired t-tests, or for comparisons between multiple conditions the main effects and simple effects were probed by one-way or two-way ANOVAs with Tukey correction for multiple comparisons. Error bars represent standard errors of the mean (SEM).
Results
Exogenous expression of C-terminal DISC1 mutant causes loss of dendritic spines and aggregates within dendrites.
Disruption in glutamatergic transmission and abnormal dendritic spine morphology and number is a cellular phenotype shared across a number of neurodevelopmental and psychiatric disorders 4, 13 . Manipulation of DISC1 function either through expression of wildtype or a C-terminal truncation mutant has previously been shown to induced spine loss in vitro 21, 23 . Therefore, we Taken together, these data reveal that both DISC1 and DISC1ΔCT causes a reduction in dendritic spine density and accumulate in dendrites where they appear to form aggregates in primary cortical neurons.
Modulation of Dendritic spine density by 17β-estradiol in neurons expressing wildtype or C-terminal truncated DISC1.
Previous studies have demonstrated that 17β-estradiol can increase dendritic spine density in cortical neurons 45, 48 . 17β-estradiol has been reported as having an inverse "U" shaped dose-dependent effect on dendritic spine density 49 . Therefore, we investigated at which dose 17β-estradiol effectively increased dendritic spine Recent work has suggested that DISC1 forms aggregates under physiological and pathological conditions 34, 41, 42 . The formation of aggregates has been proposed to contributes to DISC1's cellular function and the cellular pathology associated with the altered expression of this protein 39, 46, 47 . Intriguingly, reducing DISC1 aggregation has been linked with a reduction in cellular pathology 46, 50 . However, whether DISC1 aggregation is linked with the loss of dendritic spine density induced by overexpression, and whether modulating DISC1 aggregation could influence synaptic deficits is not known. As 17β-estradiol could restore aberrant spine density back to a level similar to basal conditions, we tested the hypothesis that it may also reduce the extent to which ectopic DISC1 aggregated. Under control conditions, both HA-DISC1 and HA-DISC1ΔCT could be observed as large clusters within the dendrite ( Figure 1C) . However, after treatment with 17β-estradiol, both HA-DISC1
and HA-DISC1ΔCT clustering was reduced, with smaller and fewer clusters evident To ensure that the effects observed above were not due to an artifact of overexpressing DISC1 constructs, we employed a second approach to alter DISC1
function. Previous studies have demonstrated that long term shRNA-mediated knockdown of DISC1 results in a loss of dendritic spine linear density in both in vitro and in vivo systems 21, 37 . Thus, reducing DISC1 expression levels has been suggested to be an approach to induce a cellular phenotype relevant for neurodevelopmental and psychiatric disorders 37 . Redistribution of DISC1 and kalirin-7 following acute 17β-estradiol treatment.
As our data indicated that 17β-estradiol could modulate the sub-cellular distribution of exogenous wildtype and mutant DISC1, we reasoned that it may also influence the distribution of endogenous DISC1 and its binding partners. Therefore, we evaluated whether acute exposure to 17β-estradiol could alter the sub-cellular localization of the DISC1/PSD-95/kalirin-7 signalosome. In support of this idea we have recently shown that 17β-estradiol causes the rapid redistribution of several synaptic proteins, including PSD-95, from dendrites into spines 48 . Importantly, the ability of DISC1 to regulate spinogenesis is thought to be mediated by its interactions with key synaptic proteins, including PSD-95 and kalirin-7 a Rac-GEF 21 . We first tested this by examining whether levels of DISC1/PSD-95/kalirin-7 were altered following treatment with 17β-estradiol. Western blotting of whole cell lysates of neurons treated with 17β-estradiol for 0 or 30 minutes, revealed no change in overall expression of DISC1 (130 and 100 kDa isoforms), kalirin-7 or PSD-95 ( Figure 3A; 'whole cell lysate'). Next, we examined the enrichment of these proteins in crude synaptosomal (P2) and cytosol (S2) fractions. This revealed that 17β-estradiol caused a loss of DISC1 130 and 100 kDa isoforms specifically within the P2 fraction, with a concurrent increase in S2 fraction (Figure 3A & B) . Figure 3C ). This was further highlighted by line scans analysis across spines, as following 17β-estradiol treatment, the intensity of DISC1 staining within dendritic spines was reduced (Supplemental Figure 4A) . Thus, these data indicate that 17β-estradiol specifically removes DISC1 from dendritic spines into non-synaptic regions.
We next sought to determine whether kalirin-7 and PSD-95 were being trafficked to the same location following 17β-estradiol treatment, by assessing the number of kalirin-7 and co-localized PSD-95/kalirin-7 puncta. Consistent with our previous data, we observed an increase in the density of PSD-95 puncta ( Figure   3D ), which we have previously shown to represent an increase of synaptic sites 48 .
Similarly, we found that treatment with 17β-estradiol resulted in an increase in total kalirin-7 puncta (kalirin-7 puncta per 10 µm: two-way ANOVA Figure 3D ). Under control conditions, 65% of kalirin-7 puncta were positive for PSD-95; a similar level of co-localization was also seen following treatment with 17β-estradiol ( Figure 3D ). Consistent with these data, we found that kalirin-7 intensity within spines increases primarily following 17β-estradiol treatment ( Figure 3E ). The enrichment of kalirin-7 within spines following treatment could also be illustrated using line scan analysis across dendritic spines (Supplemental Figure   4B ), consequently supporting our biochemical data in demonstrating that a subpopulation of kalirin-7 was being trafficked to synaptic regions following 17β-estradiol treatment. Taken together, these data demonstrate that 17β-estradiol induces a bi-directional trafficking of DISC1, kalirin-7 and PSD-95, with the former protein having a reduced synaptic enrichment, and the latter two proteins increasing in their synaptic localization.
Chronic repeated treatment with 17β-estradiol reverses spine loss induced by mutant DISC1 expression.
We next were interested in understanding whether chronic, repeated exposure to 17β-estradiol could reverse spine loss in our cellular model. To test this, One limitation of assessing spine density is that not all spine form synapses.
Therefore, we were interested in determining whether chronic, repeated treatment with 17β-estradiol was also altering the number of spines with the potential to form Figure 5A & D) . Collectively, these data provide evidence that chronic repeated exposure to 17β-estradiol is sufficient to increase the number of spines that contain the anatomical hallmarks of being able to form synapses in both control and mutant DISC1 expressing cells. Therefore, 17β-estradiol appears to be able to increase the number of excitatory synapses in a cellular model relevant for psychiatric disorders.
Discussion
In this study, we have tested the hypothesis that 17β-estradiol can restore excitatory synapses number in a cellular model that recapitulates the loss of synapses associated with SCZ and MDD. We show that in cortical neurons with reduced dendritic spine density produced by manipulating DISC1, acute treatment with 17β-estradiol increased spine density to control levels. Treatment with 17β-estradiol was also able to reduce the extent to which ectopic wildtype and mutant . However, increasing evidence suggests that the beneficial effects of 17β-estradiol may also be in part conferred through the modulation of glutamatergic signaling 27, 35, 36 . This is supported by animal studies which show that 17β-estradiol enhances performance on a number of cognitive tasks, including attention and learning and memory tasks in healthy animals 27, 28, 54 as well as models of psychosis 30, [55] [56] [57] . Importantly, it is the ability of 17β-estradiol to modulate both glutamatergic and GABAergic systems that 21 underlies these enhancing effects 45, 48, [58] [59] [60] [61] . This supports the rationale for examining whether 17β-estradiol could regulate excitatory synapses in a disease-relevant cellular model.
It is important to consider the use of DISC1 as the mediator of cellular pathology in our study. DISC1 had emerged as a candidate risk factor for major mental illnesses, including SCZ, autism spectrum disorder, bipolar disorder and MDD 15 . While DISC1 may not directly contribute to the etiology of these disorders 15, 19, 20 , it has been argued that DISC1-based cellular systems are useful in understanding cellular mechanisms relevant for neuropsychiatric disorders 13 , and in exploring potential therapeutic agents 37 . Taking advantage of the ability of DISC1 to induce spine loss, data presented in this study provides evidence that 17β-estradiol is capable of increase glutamatergic synapse number in a disease-relevant cellular model. Collectively, these data indicate that the beneficial effects of estrogens could be driven in part by the regulation of glutamatergic synapses. It should be noted, however, that these results do not negate the possibility that 17β-estradiol also modulates multiple other systems, and this also contributes to its beneficial effects in SCZ and MDD.
It is of note that in our study overexpression of both full length DISC1 or DISC1ΔCT had similar effects to reduce dendritic spine density. DISC1 has been shown to regulate spine and synapse morphology and density through its interacting partners 13, 18, 21, 41 . Therefore, there are multiple mechanisms by which DISC1 could exert its effects on synapses. For example, DISC1 regulates kalirin-7's GEF activity for Rac1, by modulating the interaction of this protein with PSD-95 21 . Overexpression of DISC1 increases the interaction between kalirin-7 and PSD-95, resulting in a decrease activation of Rac1 21 . DISC1 also interacts and regulates the activity of the 22 synaptic protein TNIK. Regulation of TNIK activity by DISC1 is required for the correct composition of synaptic proteins at synapses and synaptic number 41 . Several studies have shown that expression of mutant DISC1 lacking the C-terminal domain results in a loss of dendritic spines in vivo and in vitro indicating a critical role for the C-terminal portion of DISC1 in maintenance of spine density 22, 23, 26 . A recent study using a transgenic animal that expresses a C-terminal fragment of DISC1 in an inducible manner, demonstrated that a time-dependent loss of dendritic spine density 25 . As overexpression of the C-terminal fragment is predicted to reduce the ability of DISC1 to interact with binding partners such as NDEL1, this study provides further evidence that the C-terminal and its binding partners are critical for the maintenance and formation of dendritic spines. However, it is also interesting to note that insoluble DISC1, caused by overexpression of DISC1, is less able to bind to interacting partners such as NDEL1 39 , highlighting functional implications of aggregate formation. In our primary neuronal cultures, both DISC1 and DISC1ΔCT
constructs formed large clusters, or aggregates, along dendrites, similar to previous reports 39, 46 . Thus, it is possible that aggregation of DISC1 or DISC1ΔCT disrupts the interactome of this protein, and therefore negatively impacts the maintenance of dendritic spines. Interestingly, our data indicates that concurrent with a return of spine density to basal levels, 17β-estradiol also reduces the extent to which DISC1 forms aggregates. While a direct link between DISC1 clustering and spine deficits has not been established, it will be interesting in future studies to ascertain whether these are two separate events, or whether 17β-estradiol's ability to restore spine density to basal levels is also connected to its ability to reduced DISC1 clustering.
In support of such an idea, we show that 17β-estradiol is capable of altering the distribution of endogenous DISC1 as well. Interestingly, our data indicates 17β-estradiol reduced the synaptic content of endogenous DISC1. This is consistent with previous data indicating that endogenous DISC1 acts to limit spine formation 21 .
Activity-dependent signaling reduces the extent to which DISC1 interacts with PSD-95/kalirin-7 which in turns allows for an increase in spine size and number 21, 37 .
Consistent with this model, we show that 17β-estradiol caused the bi-directional redistribution of the DISC1/PSD-95/kalirin-7 signalsome. Whereas the presence of endogenous DISC1 at synapses is reduced following 17β-estradiol treatment, both PSD-95 and kalirin-7 are increased at synapses. This is consistent with our previous data showing that PSD-95 is targeted to nascent spines formed by 17β-estradiol 48 .
An increased presence of kalirin-7 at synapses would also be consistent with an increase in spine formation. Indeed, we have previously shown that the synaptic localization of kaliirn-7 is important for both spine maintenance and formation 62 . As PSD-95 is required for correct kalrin-7 regulation of dendritic spines, the observed increased co-localized PSD-95/kalirin-7 puncta would indicate that this complex may contribute to the formation of nascent spines. Therefore, in this model, 17β-estradiol acts to release the complex between DISC1 and PSD-95/kalirin-7, in order to allow it to engage with the machinery required for spine formation.
The data presented in this study support a role for estrogenic-modulation of dendritic spines as a potential cellular mechanism by which its beneficial effects in SCZ and MDD may occur. Owing to the link between estrogenic regulation of spines with improvement in cognitive function, especially in learning and memory 45, 60, 61 , as well as emerging data that estrogen-based compounds improve attention and working memory in male and female SCZ patients 29, 31, 33, 36 , it is intriguing to suggest that this is part of the mechanisms that underlies the beneficial actions of estrogens.
It is likely that the regulation of spines by 17β-estradiol is only part of the mechanism underlying its beneficial actions. Critically, future studies using genetic models of disease or patient iPSC models should allow for a more faithful recapitulation of both the cellular and complex genetic architecture associated with these disorders. We have shown that neurons derived from iPSC lines are responsive to estrogens 63 , demonstrating that this system could be useful for the study of estrogen-based compounds. Nevertheless, the data in this study support further investigations into estrogenic modulation of glutamatergic signaling and highlights this mechanism as having relevance for the therapeutic potential of estrogens in SCZ and MDD.
In conclusion, our data indicates that estrogens can restore lost excitatory synapses caused by altered DISC1 expression, potentially through the bi-directional trafficking of DISC1 and its interacting partners. These data highlight the possibility that estrogens exert their beneficial effects in SCZ and MDD, in part by modulating excitatory synaptic number. 
